BiotechTube
Home/OrphAI Therapeutics/Keith Fandrick, Ph.D., MBA, RAC
KF

Keith Fandrick, Ph.D., MBA, RAC

Chief Operating Officer

OrphAI Therapeutics

Therapeutic Areas

PulmonaryOncologyNeurology

OrphAI Therapeutics Pipeline

DrugIndicationPhase
LAM-001Pulmonary Hypertension associated with Interstitial Lung Disease (PH-ILD)Preclinical/Phase 1
AIT-102Transcriptionally Dysregulated TumorsPreclinical
AIT-101Amyotrophic Lateral Sclerosis (ALS)Preclinical

Leadership Team at OrphAI Therapeutics

BR
Brigette Roberts, M.D.
Chief Executive Officer, Director
PB
Paul Boni
Chief Financial Officer
PS
Patrick Sarmiere, Ph.D.
SVP, Non-clinical Research
JE
Joan Edwards
Chief Quality Assurance Officer
View full OrphAI Therapeutics profile